ResMed Inc. (RMD)
NYSE: RMDHealth CareMedical/Dental InstrumentsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
RMD stock chart
Technical analysisKey statistics
All statistics- Market cap
- $31.78B
- P/E (TTM)
- 21.67
- Forward P/E
- 17.08
- EPS (TTM)
- $10.43
- Dividend yield
- 1.06% ($2.40)
- Ex-dividend date
- Aug 20, 2026
- 52-week range
- 180.27 – 284.87
- Day range
- 221.83 – 228.75
- Volume / Avg
- 1.13M / 1.35M
- Beta
- —
- Shares outstanding
- 140.64M
- Next earnings
- Oct 29, 2026
52-week range
RMD stock today
On Oct 7, RMD ended the session at $225.98, adding $5.29 (2.40%), versus the S&P 500's 0.22% decline. Shares are 20.7% below their 52-week high of $284.87, set on Oct 8, 2025 and 25.4% above the 52-week low of $180.27, in the middle of the past year's range. RMD is down 6.2% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has lost 20.2%.
At 21.7x trailing earnings, ResMed trades below the peer-group median of 44.4x. Its forward P/E of 17.1x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year. ResMed's next earnings report is expected on Oct 29, 2026. ResMed pays an annual dividend of $2.40 per share, a 1.06% yield at the current price.
Summary generated from market data by MetaCap's automated system. Methodology
About ResMed
Company profileResMed Inc. engages in the digital health and cloud-connected medical devices business in the United States and internationally. It operates in two segments, Sleep and Breathing Health, and Residential Care Software.
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- CEO
- Mr. Michael J. Farrell BE, MBA, SM
- Headquarters
- San Diego, CA
- Employees
- 11,370
- Website
- resmed.com
Financial highlights
Full financialsIn fiscal 2026, ResMed generated $5.65 billion in revenue, up 9.9% from fiscal 2025, its 17th consecutive year of revenue growth. Net income was $1.52 billion (+8.8% year over year), for a net margin of 26.9% versus a median of 21.8% in the prior 5 years. Gross margin was 61.1% (up from 59.4%) and operating margin 33.4%.
| Fiscal year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Revenue | $5.65B | $5.15B | $4.69B | $4.22B | $3.58B |
| Growth | +9.85% | +9.84% | +10.95% | +18.02% | +11.93% |
| Net income | $1.52B | $1.40B | $1.02B | $897.56M | $779.44M |
| EPS (diluted) | $10.43 | $9.51 | $6.92 | $6.09 | $5.30 |
Analyst forecast
ForecastConsensus (20 analysts)
buy
Avg. price target
$250.22+10.73%
- Strong buy 2
- Buy 7
- Hold 10
- Sell 1
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Oct 29, 2026
- EPS estimate
- $2.70
- Last reported (Q4 2026)
- Aug 13, 2026
- EPS actual vs est.
- $2.64 vs —
Dividends
Dividend history- Annual dividend
- $2.40
- Dividend yield
- 1.06%
- Last payment
- $0.66
- Ex-dividend date
- Aug 20, 2026
RMD news
All RMD newsResMed peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| DXCMDexCom Inc. | 84.30 | +1.09% | $31.81B | vs RMD |
| WSTWest Pharmaceutical Services Inc. | 366.48 | -1.65% | $25.79B | vs RMD |
| MDLNMedline Inc. Class A | 35.45 | -0.28% | $47.70B | vs RMD |
| SOLVSolventum Corporation | 85.88 | -1.33% | $14.62B | vs RMD |
| BDXBecton Dickinson and Company | 180.16 | -0.08% | $49.07B | vs RMD |
| PENPenumbra Inc. | 316.35 | -0.22% | $12.46B | vs RMD |
| BAXBaxter International Inc. | 23.97 | -1.60% | $12.39B | vs RMD |
| GKOSGlaukos Corporation | 172.18 | +6.55% | $10.16B | vs RMD |
Indexes, lists and sector
Index membership
Appears in lists
ResMed stock FAQ
What is ResMed's stock price today?
RMD last traded at $225.98 as of Oct 7, 4:00 PM EDT, up 2.40% on the day. Prices are delayed at least 15 minutes.
Does ResMed pay a dividend?
Yes. ResMed pays $2.40 per share annually, a 1.06% yield. The most recent dividend of $0.66 had an ex-dividend date of Aug 20, 2026.
When is ResMed's next earnings date?
ResMed is expected to report earnings on Thursday, October 29, 2026. Analysts expect EPS of $2.70.
What is RMD's P/E ratio?
RMD trades at a trailing P/E ratio of 21.67 and a forward P/E of 17.08, compared with a median of 44.4 for its closest peers.
Is ResMed in the S&P 500?
Yes. ResMed (RMD) is a constituent of the S&P 500 index.
Who is ResMed's CEO?
Mr. Michael J. Farrell BE, MBA, SM is the chief executive officer of ResMed Inc., which has about 11,370 employees.
Has RMD ever split its stock?
Yes. The most recent RMD stock split was a 2-for-1 split on Aug 31, 2010, one of 4 splits on record.